Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • William Blair Initiates Coverage of Three Oil and Gas Companies

    William Blair initiated research coverage of APA Corporation, Coterra Energy Inc., and Ovintiv Inc.

    Read more

  • Developing an Investment Policy Statement for Nonprofits

    Learn how a nonprofit Investment Policy Statement (IPS) guides asset allocation, risk management, and fiduciary oversight to support long-term mission goals.

    Read more

  • Senegal’s Hidden Debt Shock

    Dan Wood speaks to us from Senegal, where bond-market volatility has spiked due to the declaration of a previously hidden stockpile of government debt.

    Watch the video
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures